PND7 - Total Migraine freedom for breath powered intranasal delivery of 22 mg Sumatriptan Powder (Avp-825) Versus 100 mg oral sumatriptan from the compass study of acute treatment of Migraine

R Halker,S Tepper,S Siegert,C Wallick

doi:10.1016/j.jval.2015.03.1627

PND7 - Total Migraine freedom for breath powered intranasal delivery of 22 mg Sumatriptan Powder (Avp-825) Versus 100 mg oral sumatriptan from the compass study of acute treatment of Migraine

R Halker, S Tepper + Show 2 more

Open Access

https://doi.org/10.1016/j.jval.2015.03.1627

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: May 1, 2015
Citations: 3	License type: publisher-specific-oa

Affiliation: Mayo Clinic, Winneshiek Medical Center, Cleveland Clinic, Avanir Pharmaceuticals (United States)

#Sumatriptan Powder #Oral Sumatriptan + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

PND7 - Total Migraine freedom for breath powered intranasal delivery of 22 mg Sumatriptan Powder (Avp-825) Versus 100 mg oral sumatriptan from the compass study of acute treatment of Migraine

Full Text